Revenue and EPS beat estimates; full-year guidance stays unchanged

The quarter cleared published expectations. The market was looking for roughly $80.5 million of revenue and $0.24 of EPS; Aurinia delivered $83.2 million and $0.28, respectively — a modest revenue beat and a more meaningful per-share beat.

The underlying commercial engine remains solid. LUPKYNIS sales rose 19% year over year to $79.4 million, driving essentially all of the quarter’s revenue beat; total revenue increased 19% to $83.2 million. (Financial Highlights)

The earnings beat was helped by more than sales growth. Operating income more than doubled to $46.3 million, aided by lower operating costs and a $6.2 million net other-income benefit versus a $9.2 million expense last year. That makes the EPS outperformance real, but less purely operational than the headline suggests. (Income Statement)

Cash generation and capital returns strengthen the read. Operating cash flow reached $52.5 million for the quarter and $85.1 million year to date, while Aurinia repurchased 5.0 million shares for $74.9 million. Cash, restricted cash and investments totaled $443.1 million at June 30, 2026, up from $398.0 million at year-end despite the buyback. (Cash Flow statement; Balance Sheet)

The main restraint is unchanged guidance. Management reiterated 2026 revenue guidance of $315 million to $325 million and net product sales guidance of $305 million to $315 million rather than raising it. That implies the beat improves confidence in execution but does not yet change the company’s stated full-year outlook. (2026 Guidance)

Pipeline activity adds optionality, not near-term value. The newly initiated PRESERVE Phase 4 study and development of aritinercept in four indications broaden the story, but the filing provides no efficacy data or milestone that materially changes near-term valuation. (Business Update)